U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07691242) titled 'Multiple Ascending Dose Study of DW4421' on June 24.
Brief Summary: Multiple Ascending Dose of DW4421, phase I
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Volunteers
Intervention:
DRUG: DW4421S-T0
DW4421 5mg
DRUG: DW4421S-T2
DW4421 15mg
DRUG: DW4421S-T1
DW4421 20mg
DRUG: DW4421S-T3
DW4421 30mg
DRUG: DW4421S
DW4421 40mg
DRUG: DW4421-3
Zastaprazan 20mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Daewon Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....